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OBJECTIVES The aim of the study was to assess the angiographic and clinical benefits of the calcium
T-channel blocker, mibefradil, in the coronary slow flow phenomenon (CSFP).
BACKGROUND The CSFP is characterized by delayed vessel opacification on angiography (Thrombolysis In
Myocardial Infarction [TIMI]-2 flow) in the absence of obstructive epicardial coronary
disease and is often associated with recurrent chest pain.
METHODS A total of 10 CSFP patients (46  9 years) underwent angiography before and 30 min after
50 mg mibefradil; off-line blinded analysis of angiographic data included comparisons of
epicardial vessel diameter, TIMI flow grade and TIMI frame count. We also performed a
randomized, double-blind, placebo-controlled, cross-over study to examine the long-term
efficacy of mibefradil 100 mg/day on the frequency of total angina, prolonged angina (i.e.,
persisting 20 min) episodes, and sublingual nitrate consumption, during consecutive
one-month treatment periods in 20 patients (age 51  12 years) with the CSFP.
RESULTS Without changing epicardial vessel diameter or rate-pressure product, mibefradil reduced the
number of vessels exhibiting TIMI-2 flow from 18 to 5; furthermore, mibefradil significantly
improved the TIMI frame count only in those vessels exhibiting TIMI-2 flow (28  18%, p
 0.005). Compared with placebo, mibefradil significantly reduced total angina frequency by
56% (p  0.001), prolonged episodes of angina by 74% (p  0.001), and sublingual nitrate
consumption by 59% (p  0.01); furthermore, mibefradil improved physical quality of life as
assessed by the Health Outcome Study Short Form-36.
CONCLUSIONS These angiographic and clinical improvements produced by mibefradil support a microspastic
pathogenesis of the CSFP. (J Am Coll Cardiol 2004;44:57–62) © 2004 by the American
College of Cardiology FoundationC
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the coronary slow flow phenomenon (CSFP) is a coronary
icrovascular disorder characterized by the delayed passage
f contrast in the absence of obstructive epicardial coronary
isease. It is well recognized by coronary angiographers but
as largely been considered an angiographic curiosity and
eceived little attention despite previous studies demonstrat-
ng coronary microvascular dysfunction (1–3).
The presentation of the CSFP differs from other coronary
icrovascular disorders, with most patients undergoing
ngiography after admission with an acute coronary syn-
rome (4), accounting for 4% of unstable angina admissions
5). The clinical course is quite debilitating, with over 80%
f patients experiencing recurrent chest pain, necessitating
eadmission to the coronary care unit in almost 20% (4).
From clinical experience, conventional antianginal ther-
py is of limited benefit in the chronic management of these
atients, with the exception of the unique calcium
-channel blocker, mibefradil. The aim of this study was to
valuate the efficacy of mibefradil in the management of the
From the *Cardiology Unit, North Western Adelaide Health Service, University of
delaide, Adelaide, Australia; †School of Applied Mathematics and ARC Special
esearch Centre for Molecular Genetics of Development, University of Adelaide,
delaide, Australia; and the ‡Department of Cardiology, Concord Repatriation
eneral Hospital, and Anzac Research Institute, University of Sydney, Sydney,
ustralia. This study did not receive any external funding support but was undertaken
ratis by hospital staff.
Manuscript received December 31, 2003; revised manuscript received March 5,d004, accepted March 16, 2004.SFP by examining the acute angiographic effects of
ibefradil on delayed vessel opacification and its chronic
ntianginal effects in affected patients.
ETHODS
wo separate studies were conducted to examine the effects
f mibefradil in the CSFP: 1) an acute angiographic study;
nd 2) a chronic antianginal efficacy study. In both studies,
SFP was defined by the consensus of at least two inde-
endent observers on the basis of: 1) angiographically
ormal or near-normal (40% stenosis) epicardial coronary
rteries; and 2) Thrombolysis In Myocardial Infarction
TIMI)-2 flow (i.e., requiring 3 beats to opacify the distal
asculature) (6) in at least one major vessel. The study
xclusion criteria were: 1) coronary slow flow after a coro-
ary intervention; 2) left ventricular systolic dysfunction
ejection fraction 50%); 3) sinus node disease; and 4)
oncurrent therapy with medications metabolized via cyto-
hrome P450 3A4, which is inhibited by mibefradil (7). The
tudy was approved by the institutional ethics committee,
nd informed consent was obtained from all patients.
cute angiographic response to mibefradil. Ten patients
ith documented coronary slow flow underwent a prospec-
ively designed investigation with blinded end point analysis
o examine the hypothesis that mibefradil acutely accelerates
istal vessel opacification in affected patients. All patients
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Mibefradil in the Coronary Slow Flow Phenomenon July 7, 2004:57–62ad been admitted with a clinical diagnosis of unstable
ngina and treated with verapamil, aspirin, intravenous
itrates, and heparin therapy. These medications were
ontinued during the coronary angiographic procedure.
Coronary angiography was performed using 6-F Judkins
atheters with images acquired at 12.5 frames/s on a Philips
ntegra angiographic system (Philips, the Netherlands).
fter baseline angiographic views, patients chewed then
wallowed a 50-mg mibefradil tablet. After a 30-min
bservation period during which heart rate, blood pressure,
nd 2-lead electrocardiogram (ECG) were continuously
onitored, angiographic views were repeated. The baseline
nd 30-min images were analyzed off-line by two indepen-
ent observers blinded to the patient and image sequence.
Proximal and distal epicardial artery diameters were
ssessed for each of the three major coronary arteries using
utomated edge detection software with pincushion distor-
ion correction and calibrated for the diagnostic catheter
iameter. The TIMI flow grade and TIMI frame count
ere assessed for each vessel utilizing criteria defined by
hesebro et al. (6) and Gibson et al. (8), respectively.
Corrected TIMI frame counts (CTFC) were calculated
o account for the greater length of the left anterior
escending artery (LAD) utilizing previously established
ethodology (8). The correction factor was determined by
nalysis of 30 patients with satisfactory angiographic views,
ho had angiographically smooth epicardial coronary arter-
es with TIMI-3 flow and normal left ventricular systolic
unction (ejection fraction50%). The mean ( SD) TIMI
rame count for the circumflex and right coronary arteries
ere similar (11  3 frames and 10  3 frames, respec-
ively) and significantly less than the LAD (19  5 frames,
 0.001). Dividing the mean TIMI frame count of the
AD by the combined value of the shorter vessels attained
correction factor of 1.7, consistent with values previously
ublished (8). Hence, the CTFC for the LAD in this
ontrol group was 11  3 frames.
Additionally, a limited time-control study was performed
o determine if CTFC changed spontaneously during the
0-min observation period. Six further patients with the
SFP underwent baseline and 30-min angiographic views
ithout the administration of mibefradil. Images were
ssessed in conjunction with the above pre-/post-mibefradil
mages so that the observer was blinded in relation to image
equence and whether mibefradil had been administered.
hronic antianginal efficacy of mibefradil. Twenty-one
Abbreviations and Acronyms
CSFP  coronary slow flow phenomenon
CTFC corrected TIMI frame count
ECG  electrocardiogram
LAD  left anterior descending artery
SF-36  Health Outcome Study Short Form-36
TIMI  Thrombolysis In Myocardial Infarctionatients with the CSFP who experienced angina at least 3 (imes a week were recruited into this investigation, includ-
ng 3 of the 10 patients who participated in the acute
ngiographic response to mibefradil study. This random-
zed, double-blind, placebo-controlled, cross-over study as-
essed the hypothesis that mibefradil reduces total angina
requency in patients with the CSFP.
The study protocol for this investigation is summarized in
igure 1. After an initial visit when clinical history and
nformed consent were obtained, patients ceased their usual
ntianginal therapy (except sublingual nitrates). One week
ater, they were randomized to placebo/mibefradil therapy
sing a computer-generated algorithm. Treatment sequence
as known only to the hospital investigational drugs phar-
acist who had no contact with the patients.
After one week of mibefradil 50 mg/placebo therapy,
atients were reviewed for tolerance of this dose, and dosage
ncreased to the 100 mg/placebo dosage. Patients continued
n this target dose for a four-week period after which they
ere clinically reassessed and commenced a one-week wash-
ut phase. Thereafter, patients crossed-over to the alterna-
ive mibefradil 50 mg/placebo treatment. If severe recurrent
hest pain occurred on the randomized treatment, incre-
ental open-labeled antianginals could be initiated in the
ollowing sequence: isosorbide mononitrate (slow release)
0 mg, 120 mg, and then nifedipine controlled-release 60
g as once daily medications.
Throughout the study period, patients maintained an
ngina diary recording the frequency and duration of angi-
al episodes as well as sublingual nitrate consumption. At
ach clinic visit, the diary was reviewed, changes in non-
tudy medication noted, adverse effects documented, and
esting heart rate and blood pressure recorded. In the last
eek of each of the randomized treatment phases, the
ollowing parameters were assessed: 1) resting 12-lead
CG; 2) 12-channel, 24-h ambulatory ECG monitoring
or ST-segment changes (utilizing Rozinn Holter for Win-
ows Version 4.1 software); 3) C-reactive protein (nephlo-
etric assay; Dade-Behring, New York) and troponin-I
immunoassay; Dade-Behring); 4) patient compliance by
ill count; and 5) quality of life assessment utilizing the
ell-validated (9) Health Outcome Study Short Form 36
igure 1. Study protocol. Summary of the 12-week study protocol includ-
ng double-blind randomization to placebo/mibefradil 50 mg therapy for
ne week followed by four weeks of placebo/mibefradil 100 mg therapy
ith cross-over to the alternative therapy after a one-week washout period.SF-36).
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July 7, 2004:57–62 Mibefradil in the Coronary Slow Flow PhenomenonThe primary end point of this investigation was the
requency of angina episodes recorded in the patient’s
ngina diary. Secondary end points were frequency of
rolonged anginal episodes (20 min), sublingual nitrate
onsumption, ST-segment changes on ambulatory ECG,
hanges in cardiac markers, and SF-36 scores. The sample
ize was calculated on the basis of a survey of eight slow flow
atients in whom mibefradil therapy reduced angina fre-
uency by 90 14% over a six-month period. Based on this
bservation, 17 coronary slow flow patients would need to
e recruited to detect a 15% reduction in chest pain
requency with a 90% power where p  0.01 (two-tailed).
ata analysis. Continuous variables were expressed as
ean  SD, unless otherwise indicated. Statistical signifi-
ance was considered at the p  0.05 level. Comparisons of
he baseline and 30-min angiographic data were made with
hi-square test and paired Student t test for categorical and
ontinuous data, respectively.
The clinical investigation of mibefradil’s chronic antian-
inal efficacy was made using appropriate cross-over trial
ethodology (10). Thus, blinded analysis of the angina
iary end points were performed by comparison between
atients with respect to treatment order utilizing Mann-
hitney U tests. Similarly, comparisons of secondary end
oint parametric data were performed with the two-sample
test for two independent samples applied appropriately to
verage differences and sums of the responses within and
etween patients. Comparisons of the SF-36 scores were
ade with analysis of variance for repeated samples.
ESULTS
cute angiographic response to mibefradil. Among the
0 patients (mean age of 46  9 years; 9 males) participat-
able 1. Hemodynamic Parameters and Coronary Diameters Pre
Pre-M
emodynamics
Heart rate (beats/min) 71
Mean arterial pressure (mm Hg) 91
Rate-pressure product (beats/min mm Hg  103) 9.2
oronary artery diameters
LAD
Proximal (mm) 3.52
Distal (mm) 1.32
Cx
Proximal (mm) 3.93
Distal (mm) 1.34
RCA
Proximal (mm) 4.40
Distal (mm) 1.69
oronary flow indexes
Vessels with the CSFP (n)
CTFC in vessels initially with TIMI-2 flow (frames) 36
CTFC in vessels initially with TIMI-3 flow (frames) 20
Mibefradil was administered as a single 50-mg oral dose.
CSFP  coronary slow flow phenomenon; CTFC  corrected TIMI frame coun
rtery; TIMI  Thrombolysis In Myocardial Infarction.ng in the angiographic study, baseline angiography dem- pnstrated smooth epicardial coronary arteries in all except
ne patient who had a 40% stenosis in the LAD and an
ctatic right coronary artery. Of the 30 major epicardial
oronary vessels systematically assessed, 18 exhibited
IMI-2 flow at baseline with the most commonly affected
eing the LAD (50%), followed by the right coronary (28%)
nd circumflex (22%) arteries.
Oral administration of 50 mg mibefradil was well-
olerated and was not associated with a significant change in
eart rate, mean arterial pressure, rate-pressure product, or
picardial coronary artery diameter during the 30-min
bservation period (Table 1). However, the coronary flow
ndexes improved after mibefradil (Fig. 2), with abolition of
he CSFP in 13 of the 18 vessels initially exhibiting the
henomenon. Furthermore, analysis of the CTFC (Table 1)
emonstrates that the effects of mibefradil in accelerating
ow were significantly greater (p  0.05) in vessels initially
xhibiting the CSFP (28  18% improvement in CTFC)
han in those vessels exhibiting TIMI-3 flow (7  35%
mprovement in CTFC) (Fig 3).
In contrast, among the six time-control patients, there
as no significant change in CTFC over the 30-min period
oth in the vessels that initially exhibited the CSFP (1 
1%, p  0.98) and those initially with TIMI-3 flow (8 
8%, p  0.19).
hronic antianginal efficacy of mibefradil. Over a 12-
onth period, 21 patients were recruited, with 1 patient
ithdrawn from the study due to visit noncompliance two
eeks after recruitment. The coronary risk factor profile of
he remaining 20 patients (mean age  51  12 years; 13
ales) included cigarette smoking in 4 (20%), hypertension
n 5 (25%), diabetes in 3 (15%), and hypercholesterolemia
total cholesterol212 mg/dl) in 11 (55%), although only 2
Post-Mibefradil in 10 Patients With the CSFP
dil Post-Mibefradil % Change p Value
69  11 3  7 0.3
94  7 4  7 0.2
9.2  2.0 1  14 0.7
2 3.68  0.82 5  8 0.2
2 1.26  0.36 5  10 0.3
9 3.98  0.61 1  3 0.3
3 1.34  0.21 1  4 0.8
7 4.50  0.75 2  3 0.053
9 1.76  0.24 4  5 0.056
5 72 0.0006
25  6 28  18 0.0001
19  8 7  35 0.3
 circumflex artery; LAD  left anterior descending artery; RCA  right coronary- and
ibefra
 10
 6
 1.7
 0.7
 0.3
 0.5
 0.2
 0.7
 0.2
18
 7
 8
t; Cxatients received lipid-lowering therapy. Index angiography
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Mibefradil in the Coronary Slow Flow Phenomenon July 7, 2004:57–62emonstrating the CSFP was undertaken after an acute
oronary syndrome presentation in 15 patients (75%). An-
iography demonstrated smooth epicardial vessels in 16
atients (80%), minor ectasia in 2, (10%) and a minor
onobstructive (40%) lesion in the remainder. Of the 60
ajor epicardial vessels, 33 exhibited the CSFP, with the
AD involved in all patients. Left ventricular systolic
unction on echocardiography was normal in all patients,
nd four (25%) had borderline criteria for left ventricular
ypertrophy. Eighteen patients underwent standard exercise
tress testing, but only five (28%) showed ST-segment
hanges consistent with ischemia. None of 10 patients who
nderwent stress myocardial scintigraphy showed evidence
f inducible ischemia.
All of the 20 patients achieved and tolerated the target
igure 2. Acute angiographic response to mibefradil. An example of the ang
oronary slow flow phenomenon (CSFP). The angiographic snapshots present
oronary artery. (A) Recorded before mibefradil administration and demonstr
t three beats, thereby confirming the diagnosis of the CSFP. (B) Demonstra
igure 3. Profile plot of angiographic response to mibefradil. The Throm
linded independent observers immediately before and 30 min after a s
henomenon (CSFP). Mibefradil selectively improved the angiographic reittle effect in the 12 vessels with TIMI-3 flow (B).ose of 100 mg mibefradil. Patient compliance was over
0% on pill count in all patients except for one with 86%
uring active treatment. There were no significant differ-
nces in prospectively examined potential adverse effects
etween mibefradil and placebo therapy.
Compared with placebo, mibefradil 100 mg produced a
ignificant fall in systolic blood pressure, diastolic blood
ressure, and rate-pressure product (Table 2). There was a
rend towards heart rate reduction although this did not
chieve statistical significance (Table 2). Mibefradil did not
lter the corrected QT interval compared with placebo
reatment (QTc  410  30 ms vs. 407  36 ms,
espectively; p  0.6).
The major end point findings from the angina diary are
ummarized in Table 3. Mibefradil 100 mg significantly
hic response to a single oral dose of 50 mg mibefradil in a patient with the
re taken exactly three heart beats after contrast filled the width of the left main
complete opacification of the left anterior descending and circumflex arteries
proved vessel opacification 30 min after mibefradil administration.
sis In Myocardial Infarction (TIMI) frame counts were assessed by two
oral 50 mg mibefradil dose in 10 patients with the coronary slow flow
e in the 18 vessels initially exhibiting the CSFP (A) (p  0.005) and hadiograp
ed we
ates in
tes imboly
ingle
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July 7, 2004:57–62 Mibefradil in the Coronary Slow Flow Phenomenoneduced total angina frequency by 56%, prolonged episodes of
ngina by 74%, and sublingual nitrate consumption by 59%.
uring the study period, there were six hospital readmissions
among five patients) for uncontrolled angina requiring intra-
enous nitrates. Only one of these occurred with the patient on
aximal mibefradil therapy. Three patients required incre-
ental open-label antianginals because of severe recurrent
hest pain on the randomized treatment. Two patients re-
uired combined isosorbide mononitrate and nifedipine in
oth cross-over phases. A third patient required isosorbide
ononitrate while on placebo therapy alone.
Twenty-four hour ambulatory ECG Holter monitoring
as undertaken in all patients in the last week of each
andomized treatment although the data were incomplete in
ne patient during the placebo phase. Consistent with the
forementioned findings, more patients experienced chest
ain when ambulatory ECG monitoring was undertaken on
lacebo as compared with mibefradil therapy (53% vs. 20%
f CSFP patients, respectively; p  0.05). Despite this, no
atient demonstrated significant ST-segment changes (i.e.,
1 mm ST-segment change for 1 min) during either
reatment phase. Furthermore, there was no significant
hange between placebo and mibefradil therapy in other
ardiac markers including C-reactive protein (3 3 mg/l vs.
 4 mg/l, respectively; p  0.05) and troponin-I (0.0 
.1 g/l vs. 0.0  0.1 g/l, respectively; p  0.05) despite
pisodes of prolonged angina.
Table 4 summarizes the findings from the eight health
oncepts of the SF-36 survey during placebo and active
reatment. Mibefradil significantly improved all elements of
hysical function, resulting in a significant increase in
verall physical health summary score compared with pla-
ebo (Table 4). Although vitality scores increased signifi-
antly after mibefradil, there was no significant change in
verall mental health scores (Table 4).
ISCUSSION
his angiographic and therapeutic investigation has dem-
nstrated that the calcium T-channel blocker mibefradil
Table 2. Changes in Hemodynamic Parameter
100 mg Therapy in 20 Patients With the CSF
Parameters
Pulse Rate (beats/min)
Systolic BP (mm Hg)
Diastolic BP (mm Hg)
Rate-pressure product (beats/min  mm Hg  103)
BP  blood pressure; CSFP  coronary slow flow phenom
Table 3. Median Values (25%, 75% Interquart
Anginal Episodes (i.e., 20 Min) and Subling
Placebo and Mibefradil 100 mg Therapy in 20
Parameter
Total angina (episodes/month)
Prolonged angina (episodes/month)
Sublingual nitrate use (tablets or sprays/month)CSFP  coronary slow flow phenomenon.arkedly improves angiographic coronary flow rates in
atients with the CSFP, and has a major effect in amelio-
ating anginal symptoms resulting in improved physical well
eing. As the CSFP is frequently associated with rest angina
4), the findings are consistent with the hypothesis that the
SFP represents a distinct microspastic form of angina
ectoris.
While previous investigators (1,2) have implicated coro-
ary microspasm in the pathogenesis of the CSFP, this is
he first controlled trial of pharmacotherapy in such pa-
ients. Mibefradil was chosen for this investigation on the
asis of encouraging initial open-label experience. This
ecision was vindicated by the findings of this study, which
howed a marked reduction in total and prolonged sponta-
eous anginal episodes resulting in an improved quality of
ife and a trend towards fewer hospitalizations with unstable
ngina. Whether other antianginal agents are effective in
his condition requires further studies. Our clinical experi-
nce in managing patients with the CSFP suggest that
rganic nitrates, beta-adrenoceptor antagonists, and con-
entional calcium L-channel blockers are of limited benefit
n controlling symptoms. Dipyridamole has been reported
o be effective in an open-label study (11).
The unique pharmacologic properties of mibefradil may
ccount for its efficacy in the CSFP. Gustafsson et al. (12)
ecently demonstrated an absence of calcium L-channels
nd an abundance of T-channels in rat microvessels. This
ay account for the persistence of the CSFP on angiogra-
hy despite background L-channel blockade with verapamil
nd its subsequent resolution with calcium T-channel
lockade by mibefradil.
Mibefradil was withdrawn from general therapeutic avail-
bility by the manufacturing company primarily because of
ts inhibition of cytochrome P450 3A4, resulting in poten-
ial accumulation of coadministered drugs (particularly sim-
astatin) metabolized via this pathway. By avoiding poten-
ially interacting drugs (e.g., utilizing pravastatin, which is
redominantly metabolized via an alternative pathway [13]),
ring Four Weeks of Placebo and Mibefradil
Placebo Mibefradil p Value
0  15 6  10 0.131
3  10 9  11 0.001
3  10 5  9 0.020
0.2  2.2 1.6  2.0 0.005
anges) of Total Anginal Episodes, Prolonged
itrate Consumption During Four Weeks of
ents With the CSFP
lacebo Mibefradil 100 mg p Value
(11, 56) 8 (3, 25) 0.001
(2, 24) 2 (0, 5) 0.001
(1, 28) 3 (0, 6) 0.01s Du
Pile R
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Mibefradil in the Coronary Slow Flow Phenomenon July 7, 2004:57–62ibefradil can be safely and effectively used because it is well
olerated. Furthermore, patients with the CSFP are typically
ounger and do not have multiple medical problems so that
ibefradil is frequently prescribed as monotherapy. Con-
idering these practical aspects and the unique clinical
roperties of mibefradil, we believe mibefradil warrants
rphan drug status for use in the CSFP.
In conclusion, the CSFP is an important, easily diag-
osed, angiographic finding attributable to coronary micro-
ascular dysfunction, which can be reversed by mibefradil.
atients with the CSFP often present initially with an acute
oronary syndrome and account for 4% of unstable angina
dmissions (5). Their subsequent progress is frequently
haracterized by remitting, relapsing anginal episodes re-
ulting in considerable impairment in quality of life, often in
oung patients. Currently available antianginal agents are
sually of limited value, but we have demonstrated that
ibefradil can both improve coronary flow and markedly
meliorate symptoms, thereby improving quality of life and
ecurrent hospitalizations in patients with the CSFP.
cknowledgments
he authors wish to express their sincere thanks to June
hallen, Dr. Terry Jones, the cardiac technicians, and the
ardiac catheterization laboratory staff for their assistance in
onducting the study. Further thanks to Michael Taylor for
ssistance in the quantification of the angiographic data and
raeme Tucker for undertaking the SF-36 data analysis.
eprint requests and correspondence: Dr. John F. Beltrame, Car-
iology Unit, North Western Adelaide Health Service, The Queen
lizabeth Hospital Campus, 28 Woodville Road, Woodville South
A 5011, Australia. E-mail: john.beltrame@adelaide.edu.au.
Table 4. The SF-36 Scores in 20 Patients Wit
Four Weeks of Placebo or Mibefradil Therapy
SF-36 Health Survey Concept
Physical health concepts
Physical functioning
Bodily pain perception
General health perceptions
Role limitation due to physical health
Physical health summary score
Mental health concepts
Vitality, energy, or fatigue
Social functioning
General mental health
Role limitation due to emotional problems
Mental health summary score
The Health Outcome Study Short Form (SF-36) scores ar
comparisons between placebo and mibefradil.EFERENCES
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